Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04178902 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma
A Phase 1 study, sponsored by AbbVie.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04178902 is a Phase 1 study that was terminated before completion, run by AbbVie. The registered enrollment target is 8 participants.
The verdict
NCT04178902, a Phase 1 study, was terminated before completion, sponsored by AbbVie.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).
Interventions
- DRUG ABBV-467
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2020-05-19 |
| Est. Completion | 2021-04-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04178902
The ClinicalTrials.gov registry entry for NCT04178902 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ABBV-467 is the first listed.
NCT04178902 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04178902 about?
NCT04178902 is a clinical study titled "A Study of the Safety and Tolerability of ABBV-467 in Adult Participants With Relapsed/Refractory (R/R) Multiple Myeloma". This first-in-human study will evaluate the safety and tolerability of ABBV-467 in adult participants with relapsed/refractory multiple myeloma (MM).
What is the current status of trial NCT04178902?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2020-05-19. Estimated completion is 2021-04-16.
What interventions are being tested in trial NCT04178902?
The interventions under investigation include: ABBV-467 (DRUG).
Who is sponsoring clinical trial NCT04178902?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.